FDA OKs Application for Immunic’s UC Therapy, Green-lighting Phase 2 Trial

FDA OKs Application for Immunic’s UC Therapy, Green-lighting Phase 2 Trial
The U.S. Food and Drug Administration has cleared the way for Immunic Therapeutics to begin a Phase 2 trial testing IMU-838, its therapy candidate for ulcerative colitis. The FDA’s approval of Immunic’s investigational new drug (IND) application allows the biotech company to initiate the clinical trial (NCT03341962), which will evaluate the safety and effectiveness of different doses of IMU-838 in

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *